SymBio PharmaceuticalsSYMQY -12.42%35 Current Ratio is 2.96 as of Dec. 2025, which is 37% below its 10-year median of 4.68. GuruFocus rates SYMQY with a GF Score™ of 35/100 and a GF Value™ of $0.50. The stock has 6 warning signs investors should review. Among 996 Drug Manufacturers companies, SymBio Pharmaceuticals ranks worse than 79.62% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. SymBio Pharmaceuticals's current ratio for the quarter that ended in Dec. 2025 was 2.96.
SymBio Pharmaceuticals has a current ratio of 2.96. It generally indicates good short-term financial strength.
The historical rank and industry rank for SymBio Pharmaceuticals's Current Ratio or its related term are showing as below:
SYMQY'
s Current Ratio Range Over the Past 10 Years
Min: 1.11 Med: 4.68 Max: 8.45
Current: 1.11
During the past 13 years, SymBio Pharmaceuticals's highest Current Ratio was 8.45. The lowest was 1.11. And the median was 4.68.
SYMQY's Current Ratio is ranked worse than 79.62% of 996
companies
in the Drug Manufacturers industry
Industry Median: 2
vs SYMQY: 1.11
SymBio Pharmaceuticals (OTCPK:SYMQY) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
SymBio Pharmaceuticals Current Ratio Related Terms
SymBio Pharmaceuticals Current Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, SymBio Pharmaceuticals's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SymBio Pharmaceuticals Current Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, SymBio Pharmaceuticals's Current Ratio distribution charts can be found below:
* The bar in red indicates where SymBio Pharmaceuticals's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SymBio Pharmaceuticals (SYMQY) has a Current Ratio of 2.96 as of Dec. 2025. This is 37% below median its historical median of 4.68. Over the past decade, SymBio Pharmaceuticals' Current Ratio has ranged from 1.11 to 8.45. According to the industry distribution chart, SymBio Pharmaceuticals ranks #793 out of 996 companies in the Drug Manufacturers industry, placing it in the top 79.6%.
Is SymBio Pharmaceuticals' Current Ratio too high?
SymBio Pharmaceuticals' current Current Ratio of 2.96 is 37% below median its 10-year median of 4.68. Over the past 10 years, this metric has ranged from a low of 1.11 to a high of 8.45. The Drug Manufacturers industry median Current Ratio is 2.00. SymBio Pharmaceuticals' value of 2.96 is 48% above this industry median. Based on the distribution chart, SymBio Pharmaceuticals ranks #793 out of 996 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, SymBio Pharmaceuticals has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does SymBio Pharmaceuticals' Current Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, SymBio Pharmaceuticals ranks #793 out of 996 companies for Current Ratio. This places SymBio Pharmaceuticals in the lower half of its industry. The industry median Current Ratio is 2.00. SymBio Pharmaceuticals' value of 2.96 is 48% above this benchmark. Historically, SymBio Pharmaceuticals' own Current Ratio has ranged from 1.11 to 8.45 over the past decade. While the company's 10-year median is 4.68 vs. the industry median of 2.00, SymBio Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Drug Manufacturers company?
The median Current Ratio among Drug Manufacturers companies is 2.00, based on 996 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. SymBio Pharmaceuticals's current Current Ratio of 2.96 is 48% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median Current Ratio is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. SymBio Pharmaceuticals's current Current Ratio is 2.96, which is 37% below median its own 10-year median of 4.68. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SymBio Pharmaceuticals stock overvalued right now?
SymBio Pharmaceuticals (SYMQY) has a current Current Ratio of 2.96. The stock's GF Value™ is $0.50, compared to a current price of $0.56 — trading 11.6% above its estimated fair value. The current Current Ratio is 2.96, which is 37% below median its 10-year median of 4.68 and 48% above the Drug Manufacturers industry median of 2.00. SymBio Pharmaceuticals' overall GF Score™ is 35/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For SymBio Pharmaceuticals (SYMQY), the current Current Ratio is 2.96 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is SymBio Pharmaceuticals (SYMQY) Overvalued in 2026?
Based on GuruFocus' analysis, SymBio Pharmaceuticals stock appears to be overvalued.
The current stock price of $0.56 is trading 11.6% above its estimated GF Value™ of $0.50.
Key valuation signals for SYMQY:
Current Ratio: 2.96 (37% below median its 10-year median of 4.68)
GF Value™: $0.50 vs. price of $0.56 (11.6% above fair value)
Industry Position: 48% above the Drug Manufacturers median (#793 of 996)
No single metric tells the full story. See the SYMQY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
SymBio Pharmaceuticals Ltd is a biopharmaceutical company engaged in development of new drugs with a primary focus on the treatment of rare diseases, mainly in the areas of oncology, hematology and multiple viral infections, and conduct integrated business activities that encompass search for new drug candidates, development, manufacturing, and sales.
35GF Score
Get the complete analysis for SYMQY
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SYMQY has been successfully added to your 
